Business
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing
About this update from Caribou Biosciences, Inc.
[{"type":"text","content":"BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose expansion data. Details of the poster presentation are as follows: Title: A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated Phase 1 results from the ANTLER trialPresenter: Boyu Hu, MD, assistant professor, director of lymphoma and CLL, division of hematology/hematologic malignancies, Huntsman Cancer Institute at the University of UtahDate and time: Monday, June 3, 2024, 9:00 am-12:00 pm CDTSession: Hematologic Malignancies – Lymphoma and CLL Location: McCormick Place, ChicagoAbstract number: 7025 The AMpLify poster will provide details on the clinical trial design and objectives. Details of the poster presentation are as follows: Title: A first-in-human Phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify)Presenter: Naval Daver, MD, associate professor and director of the Leukemia Research Alliance Program, department of leukemia, The University of Texas MD Anderson Cancer CenterDate and time: Monday, June 3, 2024, 9:00 am-12:00 pm CDTSession: Hematologic Malignancies – Leukemia, Myelodysplastic syndromes, and allotransplantLocation: McCormick PlaceAbstract number: TPS6586 Abstracts will be available on the 2024 ASCO Annual Meeting website on May 23, 2024 at 4:00 pm CDT. Poster presentations will be available on the Scientific Publications page of Caribou’s website on Monday, June 3, 2024 at 9:00 am CDT. About CB-010CB-010 is the lead clinical-stage product candidate from Caribou’s allogeneic CAR-T cell therapy platform, and it is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 clinical trial and will be evaluated in patients with lupus nephritis (LN) and extrarenal lupus (ERL) in the...